DarioHealth Corp

DarioHealth operates with a capital structure that shows a debt-to-equity ratio of 0.45, indicating a relatively conservative leverage position. The company holds $26.0 million in cash and equivalents but has $30.8 million in long-term debt, resulting in a net cash position of -$4.7 million. This liquidity profile is classified as medium risk, with free cash flow of -$38.7 million and operating cash flow of -$25.9 million in the latest period.

Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of $41.7 million and an operating loss of $40.5 million, with a return on equity of -61.4% and return on assets of -37.9%. These results contrast sharply with the industry's preferred metrics of positive ROIC and stable EBITDA margins. Gross profit of $12.7 million on $22.4 million in revenue yields a 56.7% margin, but this is insufficient to offset operating expenses.

Geographically, DarioHealth's revenue is concentrated in the United States, with no material disclosures of international operations in the latest financials. The company's business is entirely focused on digital health solutions, with no segmental breakdown provided in the available data.

Growth trajectory analysis shows a challenging outlook. The company's revenue of $22.4 million represents a decline from prior periods, with no clear path to positive growth in the current fiscal year. Analysts project a mean price target of $18.50, implying a 122% upside from the current market price of $8.30. However, the company's negative cash flows and operating losses suggest significant execution risk.

Risk factors include liquidity constraints and the potential for dilution. The company has a low dilution risk rating, but its negative net cash position and high free cash burn raise concerns about capital preservation. No recent equity issuance or ATM programs are disclosed in the available data.

Recent events include a 10-K filing that details ongoing challenges in scaling operations and achieving profitability. The company has not issued any material earnings guidance or product announcements in the last 90 days.